8-K: Sensei Biotherapeutics Announces Full Year 2023 Financial Results and Provides Clinical Update on SNS-101

Sensei Biotherapeutics reported its full year 2023 financial results and provided an update on its lead candidate SNS-101, including an accelerated timeline for topline data.

Summary

• Sensei Biotherapeutics announced its full year 2023 financial results, highlighting a net loss of $34.1 million, compared to a $48.6 million loss in 2022.
• The company's cash position was $65.8 million as of December 31, 2023, which is expected to fund operations into the fourth quarter of 2025.
• Research and development expenses decreased to $18.3 million in 2023 from $30.4 million in 2022, primarily due to lower manufacturing and personnel costs.
• General and administrative expenses also decreased to $18.8 million in 2023 from $19.8 million in 2022.
• The company is focused on its lead candidate, SNS-101, an anti-VISTA antibody, which has shown a favorable safety and pharmacokinetic profile in clinical trials.
• Topline efficacy and biomarker data for SNS-101 is now expected in the second quarter of 2024, ahead of previous guidance.
• A total of 33 patients have been treated with SNS-101, with no dose-limiting toxicities observed.
• Sensei has paused preclinical work on other programs to focus on the SNS-101 clinical trial.

Sentiment

Score: 7

Explanation: The document is generally positive due to the accelerated timeline for clinical data and the favorable safety profile of SNS-101. However, the company is still operating at a loss and has reduced R&D spending, which tempers the overall sentiment.

Positives

• The clinical trial of SNS-101 is progressing well with a favorable safety profile and no dose-limiting toxicities.
• The timeline for topline efficacy data has been accelerated to Q2 2024.
• The company has a strong cash position that is expected to fund operations into the fourth quarter of 2025.
• SNS-101 has demonstrated potentially best-in-class pharmacokinetics.
• The company has secured collaborations with the National Cancer Institute and Regeneron.

Negatives

• The company reported a net loss of $34.1 million for the year ended December 31, 2023.
• Cash reserves decreased from $107.1 million to $65.8 million year over year.
• Research and development expenses decreased, but this was partly due to pausing other preclinical programs.
• The company has paused IND-enabling work on its preclinical-stage TMAb programs.

Risks

• There are risks inherent in the development of therapeutic product candidates, including the possibility that SNS-101 may not be successfully developed or commercialized.
• There is a risk of delay or cessation of planned clinical trials.
• The company is dependent on third-party suppliers and manufacturers.
• There are risks regarding the accuracy of the company's estimates of expenses and capital requirements.
• The company may need additional financing in the future.

Future Outlook

Sensei expects its current cash balance to fund operations into the fourth quarter of 2025 and plans to share topline efficacy and biomarker data for SNS-101 in the second quarter of 2024. The company will also focus on preparations for an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2024.

Management Comments

• John Celebi, President and Chief Executive Officer, stated that initial data for SNS-101 supports a favorable and potentially best-in-class clinical safety and PK profile.
• Management is directing attention toward preparations for an end-of-Phase 1 meeting with FDA in the fourth quarter of 2024.

Industry Context

The development of SNS-101, an anti-VISTA antibody, is part of a broader trend in immuno-oncology to target novel immune checkpoints beyond PD-1/PD-L1. The company's focus on the tumor microenvironment and conditionally active antibodies aligns with current research in the field.

Comparison to Industry Standards

• Sensei's SNS-101 is being developed as a potential best-in-class anti-VISTA therapy, which is a novel target in immuno-oncology.
• Other companies are also exploring VISTA as a target, but Sensei claims to be the first to reach pharmacologically relevant dose levels in a clinical study.
• The company's approach of using conditionally active antibodies is similar to other companies developing next-generation immunotherapies.
• The reported safety and pharmacokinetic profile of SNS-101 is being compared to other checkpoint inhibitors in development.

Management Changes

Stakeholder Impact

• Shareholders may be positively impacted by the accelerated timeline for clinical data and the extended cash runway.
• Employees may be impacted by the realignment of resources and the pausing of some preclinical programs.
• Patients with advanced solid tumors may benefit from the development of SNS-101.
• The company's collaborations with the NCI and Regeneron may benefit the broader scientific community.

Next Steps

• Sensei plans to report topline efficacy and biomarker data for SNS-101 in Q2 2024.
• The company will prepare for an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2024.
• Sensei will continue to enroll patients in the dose expansion arms of the SNS-101 clinical trial.
• Preclinical work to characterize selected lead antibodies, including their mechanisms of action, and target biology is expected to continue throughout 2024.

Key Dates

Keywords

SNS-101, VISTA, immuno-oncology, clinical trial, cancer therapeutics, pharmacokinetics, dose escalation, biomarker data, TMAb, anti-VISTA antibody